AVNS Form 3: Scott Galovan Discloses Equity Holdings and Option Grants
Rhea-AI Filing Summary
Scott M. Galovan, SVP and Chief Financial Officer of Avanos Medical, reported beneficial ownership of 111,009 shares of common stock on Form 3 filed for the 08/01/2025 event. Of those shares, 80,718 are unvested time-based restricted share units that vest on scheduled dates through August 1, 2028. The filing also lists employee stock options totaling 26,582 underlying shares with varying exercise prices and vesting/exercise dates.
Positive
- Significant reported stake: 111,009 shares indicate meaningful insider ownership
- Long-term alignment: 80,718 TRSUs vesting through 2028 align executive incentives with shareholders
Negative
- None.
Insights
TL;DR: Routine insider ownership disclosure showing management alignment without material corporate events.
The Form 3 discloses an insider stake of 111,009 shares, heavily weighted toward unvested TRSUs (80,718), plus 26,582 underlying option shares across multiple grant vintages and exercise prices from $15.24 to $52.10. This is a standard initial Section 16 filing for a senior executive and does not, by itself, indicate material corporate developments or liquidity events. The mix of long-dated and near-term vesting schedules implies ongoing incentive alignment over 2026–2028.
TL;DR: Disclosure confirms executive equity compensation structure and staged vesting, typical for governance alignment.
The report confirms that the CFO holds a significant equity position primarily through TRSUs and stock options, with explicit vesting schedules through 2028. From a governance perspective, the presence of time-based restricted share units and multi-year option vesting supports long-term alignment between management and shareholders. No departures, new grants beyond those listed, or related-party transactions are disclosed in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Employee Stock Option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- Of these shares, 80,718 are represented by unvested time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. These TRSUs will vest as follows: (i) 7,821 on March 6, 2026; (ii) 3,235 on March 7, 2026; (iii) 12,225 on April 22, 2026; (iv) 13,661 on August 1, 2026; (v) 5,330 on March 6, 2027; (vi) 3,236 on March 7, 2027; (vii) 13,661 on August 1, 2027; (viii) 3,334 on March 7, 2028; and (ix) 18,215 on August 1, 2028. Each TRSU is the economic equivalent of one share of Common Stock. These options vested 30% on May 5, 2017, 30% on May 5, 2018, and 40% on May 5, 2019. These options vested 30% on May 3, 2018, 30% on May 3, 2019, and 40% on May 3, 2020. These options vested 30% on May 3, 2019, 30% on May 3, 2020, and 40% on May 3, 2021. These options vested 30% on May 8, 2020, 30% on May 8, 2021, and 40% on May 8, 2022. These options vested 30% on May 7, 2021, 30% on May 7, 2022, and 40% on May 7, 2023. These options will vest 30% on March 7, 2026, 30% on March 7, 2027 and 40% on March 7, 2028.
